FUNDAMENTALS · Fundamentals · US Healthcare

Advanced Biomed Inc. Common Stock (ADVB) Fundamentals 2026 — Revenue Analysis | SniperIQ

Advanced Biomed Inc. Common Stock (ADVB) is a US-listed Healthcare company in Medical - Diagnostics & Research with a market capitalization of

5M, trading at
4.14 on the NASDAQ. This SniperIQ fundamentals page covers Advanced Biomed Inc. Common Stock's valuation, profitability (net margin 0.0%), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap
5M
Net Margin0.0%

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Advanced Biomed Inc. Common Stock's market cap?

Advanced Biomed Inc. Common Stock (ADVB) has a market capitalization of approximately

5M, trading at
4.14 on the NASDAQ. Market cap moves with the live share price.

What is Advanced Biomed Inc. Common Stock's P/E ratio?

Advanced Biomed Inc. Common Stock's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 2.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Advanced Biomed Inc. Common Stock?

Advanced Biomed Inc. Common Stock runs a net profit margin of 0.0%, a gross margin of 0.0%, and an operating margin of 0.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

Does Advanced Biomed Inc. Common Stock pay a dividend?

Advanced Biomed Inc. Common Stock does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Advanced Biomed Inc. Common Stock financially healthy?

Advanced Biomed Inc. Common Stock carries a debt-to-equity ratio of 0.08x and a current ratio of 7.38x, with a market beta of 0.53. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Advanced Biomed Inc. Common Stock a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Advanced Biomed Inc. Common Stock (ADVB) the key facts are: market cap

5M, 52-week range 3.61-14.14. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Advanced Biomed Inc. Common Stock's full fundamentals live

Get Advanced Biomed Inc. Common Stock's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Cyclerion Therapeutics (CYCN) fundamentals · VYNE Therapeutics (VYNE) fundamentals · NeuroSense Therapeutics (NRSN) fundamentals · Optimi Health (OPTH) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons